Emergent BioSolutions to Release Second Quarter 2021 Financial Results and Conduct a Conference Call on July 29, 2021
15 juil. 2021 06h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., July 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, July 29, 2021 at 5:00 pm eastern time to discuss the financial...
COVID-19 Vaccine Drug Substance Manufactured by Emergent BioSolutions Authorized as Part of Johnson & Johnson’s Emergency Use Authorization
11 juin 2021 16h35 HE
|
Emergent BioSolutions
Emergent continues to work with the FDA to address identified observations at Bayview facility in order to release additional batches and resume production GAITHERSBURG, Md., June 11, 2021 (GLOBE...
Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate
26 mai 2021 06h30 HE
|
Emergent BioSolutions
A dose-related increase in immune response, as measured by anti-chikungunya virus serum neutralizing antibodies (SNA), was previously observed. Two years post-vaccination, SNA mean titers were 19...
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 20, 2021 at 9:00am EDT
06 mai 2021 06h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., May 06, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2021 Annual Meeting of Stockholders will be held in a virtual-only format via live...
Emergent BioSolutions to Participate in Investor Conferences
05 mai 2021 16h05 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following...
Emergent BioSolutions Reports Financial Results for First Quarter 2021
29 avr. 2021 16h05 HE
|
Emergent BioSolutions
Revises 2021 Financial Forecast GAITHERSBURG, Md., April 29, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter ended March 31, 2021. ...
Statement on Issuance of Form FDA 483 at Emergent Bayview Facility
21 avr. 2021 12h46 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., April 21, 2021 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration (FDA) has completed its inspection of Emergent BioSolutions’ (NYSE:EBS) Baltimore-Bayview facility and...
Emergent BioSolutions to Release First Quarter 2021 Financial Results and Conduct a Conference Call on April 29, 2021
15 avr. 2021 06h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., April 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 29, 2021 at 5:00 pm eastern time to discuss the financial...
Emergent BioSolutions On Track with Respect to COVID-19 Contractual Commitments; Receives Modified Task Order from the U.S. Department of Health & Human Services to Support the Opportunity for Further Expansion of Manufacturing Capacity for Johnson & Johnson’s COVID-19 Vaccine
04 avr. 2021 22h09 HE
|
Emergent BioSolutions
HHS has increased Emergent’s task order by $23 million to purchase additional biologics manufacturing equipmentReaffirms 2021 financial guidanceGAITHERSBURG, Md., April 04, 2021 (GLOBE NEWSWIRE) --...
Emergent BioSolutions Announces Topline Data from NIAID Phase 3 ITAC Trial (INSIGHT-013) Evaluating Immunoglobulins as a Treatment for Hospitalized Patients with COVID-19
02 avr. 2021 08h00 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., April 02, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today provided an update on the evaluation of its investigational SARS-CoV-2 Immune Globulin Intravenous...